Research press release



Virology: Anti-parasitic drug may protect against lung cell fusion induced by SARS-CoV-2

条虫症の治療に一般的に使用される薬剤が、新型コロナウイルス感染症(COVID-19)患者の肺の中で起こる非定型な融合細胞の形成を阻止するために役立つ可能性があることが実験室実験によって明らかになった。この研究結果を報告する論文が、Nature に掲載される。/p>


今回、Mauro Giaccaたちは、2020年3~5月にCOVID-19で死亡した患者(41人)の肺から採取した検体を調べたところ、多くの肺組織の中に融合した肺上皮細胞が含まれていることを見いだした。この融合細胞は、合胞体と呼ばれ、20個以上の核が含まれていることもあった。Giaccaたちは、このように細胞が融合する過程がSARS-CoV-2のスパイクタンパク質によって媒介されることも見いだした。スパイクタンパク質は、カルシウム振動とTMEM16Fタンパク質の活性化を引き起こす。


A drug that is commonly used to treat tapeworm infections might help to prevent the formation of atypical fused cells in the lungs of patients with COVID-19, according to laboratory experiments reported this week in Nature.

Niclosamide was originally developed in the 1950s as a molluscicide against snails. It was later approved for use against tapeworm infections in humans, and is already known to be active against various viruses, including SARS-CoV-2.

Mauro Giacca and colleagues studied post-mortem samples from the lungs of 41 patients who had died from COVID-19 between March and May 2020, and found that the tissue often contains lung epithelial cells that have become fused together. Some of these fused cells, known as syncytia, contain over 20 different nuclei. The authors found that this fusion process is mediated by the spike protein of SARS-CoV-2, which triggers calcium oscillations and the activation of a protein called TMEM16F.

On the basis of these observations, the authors screened over 3,000 clinically approved drugs to look for molecules that block this spike-driven fusion of cells. The screen identified 83 drugs, and further experiments focused on 43 molecules that also protected against viral replication and cell damage. Of these, one of the most effective molecules was the anti-parasitic drug niclosamide. This drug was found to inhibit viral replication, blunt calcium oscillation in spike-expressing cells, suppress the activity of TMEM16F and prevent the formation of spike-induced syncytia in laboratory tests. The authors note that other drugs that are known to inhibit members of the TMEM16 family of proteins also performed well in their tests and could warrant further investigation as treatments for COVID-19.

After the embargo ends, the full paper will be available at:

doi: 10.1038/s41586-021-03491-6

「Nature 関連誌注目のハイライト」は、ネイチャー広報部門が報道関係者向けに作成したリリースを翻訳したものです。より正確かつ詳細な情報が必要な場合には、必ず原著論文をご覧ください。

メールマガジンリストの「Nature 関連誌今週のハイライト」にチェックをいれていただきますと、毎週最新のNature 関連誌のハイライトを皆様にお届けいたします。